Adalimumab Treatment for Refractory Ocular Toxocariasis: Case Report
10.21561/jor.2026.11.1.69
- Author:
Kyeung Min KIM
1
;
Seung Woo CHOI
;
Se Joon WOO
Author Information
1. Department of Ophthalmology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea
- Publication Type:CASE REPORT
- From:
Journal of Retina
2026;11(1):69-74
- CountryRepublic of Korea
- Language:English
-
Abstract:
Purpose:We evaluated the therapeutic efficacy of adalimumab in patients with refractory ocular toxocariasis (OT).Case summary: Three patients with recurrent OT who experienced frequent relapses or intolerance to corticosteroids and immunosuppressants were treated with adalimumab. All three achieved improved control of intraocular inflammation, a marked reduction in relapse rate (from 2.48 to 0.14 per year), and complete discontinuation of systemic corticosteroids and immunosuppressants by the final follow-up. No adverse events were observed during adalimumab treatment. Cases 1 (bilateral panuveitis), 2 (intermediate uveitis), and 3 (neuroretinitis) each demonstrated clinical improvement or stabilization following adalimumab initiation, with remission sustained for 30–62 months.
Conclusions:Adalimumab is effective in controlling inflammation and preventing recurrence in patients with refractory OT unresponsive to conventional therapy. It may offer a viable steroid-sparing option for managing chronic inflammation in OT.
